AC-301

AC-301 is a small-molecule inhibitor targeting **receptor-interacting protein kinase 1 (RIPK1)**, developed by **Accro Bioscience**. RIPK1 is a crucial mediator of regulated cell death pathways, specifically **necroptosis**, and plays a significant role in pro-inflammatory signaling. By inhibiting the kinase activity of RIPK1, AC-301 prevents the formation of the necrosome complex, thereby blocking cell lysis and the subsequent release of pro-inflammatory damage-associated molecular patterns (DAMPs). This mechanism makes AC-301 a promising candidate for the treatment of various conditions characterized by dysregulated cell death and inflammation, including **hematological malignancies** such as diffuse large B-cell lymphoma (DLBCL) and leukemia, as well as chronic inflammatory and autoimmune diseases. The compound is part of Accro Bioscience's broader pipeline focusing on regulated cell death pathways like necroptosis, apoptosis, and ferroptosis.